NCT06435910 Engineered Dendritic Cell Vaccines for Multiple Myeloma
| NCT ID | NCT06435910 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Shenzhen Geno-Immune Medical Institute |
| Condition | Multiple Myeloma or Plasmacytoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-05-11 |
| Primary Completion | 2027-07-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2024-05-11 with a primary completion date of 2027-07-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Eligibility Criteria
Inclusion Criteria: * Male and female subjects with multiple myeloma or plasmacytoma * Very good partial or complete remission (CR) after prior combination therapies. * Expected survival \> 12 weeks * Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal * Voluntary informed consent is given with willingness to continue follow up Exclusion Criteria: * Pregnant or lactating women * Uncontrolled active infection * HIV or active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06435910 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Multiple Myeloma or Plasmacytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06435910 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06435910 currently recruiting?
Yes, NCT06435910 is actively recruiting participants. Contact the research team at c@szgimi.org for enrollment information.
Where is the NCT06435910 trial being conducted?
This trial is being conducted at Shenzhen, China, Vladivostok, Russia.
Who is sponsoring the NCT06435910 clinical trial?
NCT06435910 is sponsored by Shenzhen Geno-Immune Medical Institute. The trial plans to enroll 10 participants.